Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.9700
+0.0070 (0.73%)
At close: Dec 5, 2025, 4:00 PM EST
1.020
+0.050 (5.14%)
After-hours: Dec 5, 2025, 7:29 PM EST
Nexalin Technology Revenue
Nexalin Technology had revenue of $18.15K in the quarter ending September 30, 2025, a decrease of -49.63%. This brings the company's revenue in the last twelve months to $156.93K, down -3.18% year-over-year. In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth.
Revenue (ttm)
$156.93K
Revenue Growth
-3.18%
P/S Ratio
89.53
Revenue / Employee
$26,155
Employees
6
Market Cap
18.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NXL News
- 3 days ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 4 days ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 18 days ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire
- 23 days ago - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel - GlobeNewsWire
- 4 weeks ago - Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia - GlobeNewsWire
- 5 weeks ago - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel - GlobeNewsWire
- 6 weeks ago - Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies - GlobeNewsWire
- 7 weeks ago - Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs - GlobeNewsWire